Background: Urolithiasis (kidney stone disease) is a common urological disorder worldwide, and its management is frequently limited by recurrence, adverse effect and cost, prompting interest in plant-based alternatives. Peltophorum pterocarpum (Fabaceae) is traditionally used for fever, skin disorders, diabetes, hypertension and inflammation, and its leave are reported to contain flavonoids, tannis, phenolics, terpenoids and glycosides. Objectives: To evaluate the anti-urolithiatic potential of the alcoholic extract of P. pterocarpum leaves (ALEPP) in an ethylene glycol (EG)-induced urolithiasis model in rats. Methods: ALEPP was obtained by Soxhlet extraction (95% ethanol) of shade-dried, authenticated leaf powder and screened for phytoconstituents. Acute oral toxicity was assessed as per OECD guidelines. Urolithiasis was induced in Wistar rats by 0.5% EG in drinking water for 42 days. Five groups (n=6) received distilled water (normal control), EG (Toxicant group), EG + Cystone (750mg/kg), EG+ALEPP (100mg/kg), EG+ALEPP (400mg/kg) with treatment from day 22 to 42 day. Serum creatinine, calcium and uric acid were estimated at the end of the study. Results: EG administration markedly raised serum creatinine, calcium and uric acid relative to normal controls, confirming induction of urolithiasis. ALEPP lowered all three parameters in a dose-dependent manner; at 400mg/kg the reduction approached that produced by the standard drug cystone, while 100mg/kg produced a smaller effect. Conclusion: The alcoholic leaf extract of P. pterocarpum shows dose-dependent anti-urolithiatic activity in the ethylene glycol-induced rat model, supporting further isolation and mechanistic evaluation of its active constituents.
No takes yet. Share an insight, caveat, or question.
Parmeshappa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: